Literature DB >> 27670282

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.

Aman P Singh1, Sharad Sharma1, Dhaval K Shah2.   

Abstract

Antibody-drug conjugates (ADCs) are designed to target antigen expressing (Ag+) cells in a tumor. Once processed by the Ag+ cells, ADCs can release cytotoxic drug molecules that can diffuse out of Ag+ cells into the neighboring antigen-negative (Ag-) cells to induce their cytotoxicity. This additional efficacy of ADCs on Ag- cells in the presence of Ag+ cells is known as the 'bystander effect'. Although the importance of this phenomena is widely acknowledged for effective killing of a heterogeneous tumor, the rate and extent of the bystander killing in a heterogeneous system is not quantitatively understood yet. Thus, the objectives of this manuscript were to: (1) synthesize and characterize a tool ADC Trastuzumab-vc-MMAE that is capable of exhibiting bystander effect, (2) quantify the time course of the bystander effect for the tool ADC using in vitro co-culture systems created using mixture of various HER2-expressing cell lines, and (3) develop a pharmacodynamic (PD) model that is capable of characterizing the bystander effect of ADCs. Co-culture studies conducted using GFP labelled MCF7 cells as Ag- cells and N87, BT474, and SKBR3 as Ag+ cells revealed that the bystander effect of ADC increases with increasing fraction of Ag+ cells in a co-culture system, and with increased expression level of target on Ag+ cells. A notable lag time after ADC incubation was also observed prior to significant bystander killing of Ag- cells. Based on our results we hypothesize that there may be other determinants apart from the antigen expression level that can also influence the ability of Ag+ cells to demonstrate the bystander effect in a co-culture system. The co-culture analysis also suggested that the bystander effect of the ADC can dissipate over the period of time as the population of Ag+ cells declines. A novel PD model was developed to mathematically characterize the bystander effect of ADCs by combining two different cell distribution models to represent the population of Ag+ and Ag- cells in a co-culture system. This PD model can be integrated with the systems PK model for ADCs in the future to generate a quantitative framework that is capable of supporting the discovery and development of novel ADCs with optimal bystander killing capabilities.

Entities:  

Keywords:  Antibody–drug conjugates; Bystander effect; Co-culture system; Pharmacodynamic modeling; Tumor heterogeneity

Mesh:

Substances:

Year:  2016        PMID: 27670282      PMCID: PMC5112145          DOI: 10.1007/s10928-016-9495-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  27 in total

1.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

2.  The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

Authors:  Miranda M C van der Lee; Patrick G Groothuis; Ruud Ubink; Monique A J van der Vleuten; Tanja A van Achterberg; Eline M Loosveld; Désirée Damming; Daniëlle C H Jacobs; Myrthe Rouwette; David F Egging; Diels van den Dobbelsteen; Patrick H Beusker; Peter Goedings; Gijs F M Verheijden; Jacques M Lemmens; Marco Timmers; Wim H A Dokter
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

Review 3.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

4.  Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  AAPS PharmSci       Date:  2002

5.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

6.  Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Authors:  Yelena V Kovtun; Charlene A Audette; Yumei Ye; Hongsheng Xie; Mary F Ruberti; Sara J Phinney; Barbara A Leece; Thomas Chittenden; Walter A Blättler; Victor S Goldmacher
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

7.  Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

Authors:  Monica Simeoni; Paolo Magni; Cristiano Cammia; Giuseppe De Nicolao; Valter Croci; Enrico Pesenti; Massimiliano Germani; Italo Poggesi; Maurizio Rocchetti
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

8.  A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Authors:  John Y Li; Samuel R Perry; Vanessa Muniz-Medina; Xinzhong Wang; Leslie K Wetzel; Marlon C Rebelatto; Mary Jane Masson Hinrichs; Binyam Z Bezabeh; Ryan L Fleming; Nazzareno Dimasi; Hui Feng; Dorin Toader; Andy Q Yuan; Lan Xu; Jia Lin; Changshou Gao; Herren Wu; Rakesh Dixit; Jane K Osbourn; Steven R Coats
Journal:  Cancer Cell       Date:  2016-01-11       Impact factor: 31.743

9.  Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

Authors:  Sandhya Girish; Manish Gupta; Bei Wang; Dan Lu; Ian E Krop; Charles L Vogel; Howard A Burris Iii; Patricia M LoRusso; Joo-Hee Yi; Ola Saad; Barbara Tong; Yu-Waye Chu; Scott Holden; Amita Joshi
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-20       Impact factor: 3.333

10.  Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.

Authors:  Yusuke Ogitani; Katsunobu Hagihara; Masataka Oitate; Hiroyuki Naito; Toshinori Agatsuma
Journal:  Cancer Sci       Date:  2016-06-22       Impact factor: 6.716

View more
  27 in total

1.  Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect.

Authors:  Aman P Singh; Gail M Seigel; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Hsuan-Ping Cheng; Dhaval K Shah
Journal:  J Pharmacol Exp Ther       Date:  2020-04-09       Impact factor: 4.030

2.  Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.

Authors:  Aman P Singh; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2017-08-18       Impact factor: 3.922

3.  Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.

Authors:  Aman P Singh; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Greg M Thurber; Dhaval K Shah
Journal:  AAPS J       Date:  2020-01-14       Impact factor: 4.009

Review 4.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

5.  A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.

Authors:  Aman P Singh; Dhaval K Shah
Journal:  J Pharm Sci       Date:  2019-02-18       Impact factor: 3.534

6.  Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.

Authors:  Cornelius Cilliers; Bruna Menezes; Ian Nessler; Jennifer Linderman; Greg M Thurber
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

7.  Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.

Authors:  Sharad Sharma; Zhe Li; David Bussing; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2020-02-21       Impact factor: 3.922

8.  Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Authors:  Hsuan-Ping Chang; Zhe Li; Dhaval K Shah
Journal:  Pharm Res       Date:  2022-01-19       Impact factor: 4.200

9.  Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.

Authors:  Yingying Xu; Yakun Wang; Jifang Gong; Xiaotian Zhang; Zhi Peng; Xinan Sheng; Chenyu Mao; Qingxia Fan; Yuxian Bai; Yi Ba; Da Jiang; Fen Yang; Changsong Qi; Jian Li; Xicheng Wang; Jun Zhou; Ming Lu; Yanshuo Cao; Jiajia Yuan; Dan Liu; Zhenghang Wang; Jianmin Fang; Lin Shen
Journal:  Gastric Cancer       Date:  2021-05-04       Impact factor: 7.701

10.  Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect.

Authors:  K C Nicolaou; Stephan Rigol; Emmanuel N Pitsinos; Dipendu Das; Yong Lu; Subhrajit Rout; Alexander W Schammel; Dane Holte; Baiwei Lin; Christine Gu; Hetal Sarvaiya; Jose Trinidad; Nicole Barbour; Amanda M Valdiosera; Joseph Sandoval; Christina Lee; Monette Aujay; Hanan Fernando; Anukriti Dhar; Holger Karsunky; Nicole Taylor; Marybeth Pysz; Julia Gavrilyuk
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.